SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-029207
Filing Date
2024-03-11
Accepted
2024-03-11 16:02:08
Documents
13
Period of Report
2024-03-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ctmx-20240311.htm   iXBRL 8-K 40567
2 EX-99.1 ctmx-ex99_1.htm EX-99.1 198219
  Complete submission text file 0000950170-24-029207.txt   367225

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ctmx-20240311.xsd EX-101.SCH 24831
14 EXTRACTED XBRL INSTANCE DOCUMENT ctmx-20240311_htm.xml XML 4725
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

IRS No.: 273521219 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37587 | Film No.: 24737925
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)